ONDINE BIOMEDICAL INC.CDI Market Cap ($54.97 Million)
Market Cap & Net Worth: ONDINE BIOMEDICAL INC.CDI (VF5)
ONDINE BIOMEDICAL INC.CDI market cap. ONDINE BIOMEDICAL INC.CDI (F:VF5) has a market capitalization of $54.97 Million (€47.02 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #21354 globally and #1913 in its home market, demonstrating a -7.18% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ONDINE BIOMEDICAL INC.CDI's stock price €0.09 by its total outstanding shares 519551468 (519.55 Million). Also see how efficiently does ONDINE BIOMEDICAL INC.CDI generate cash for how efficiently the company converts equity into cash flow.
ONDINE BIOMEDICAL INC.CDI Market Cap History (2022–2026)
ONDINE BIOMEDICAL INC.CDI market cap history from 2022 to 2026. Data shows change from $126.34 Million to $54.97 Million (-33.48% CAGR). Check ONDINE BIOMEDICAL INC.CDI (VF5) share price today for real-time trading data and today's change.
ONDINE BIOMEDICAL INC.CDI Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ONDINE BIOMEDICAL INC.CDI's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore VF5 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
22.97x
ONDINE BIOMEDICAL INC.CDI's market cap is 22.97 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $126.34 Million | $638.00K | -$19.37 Million | 198.03x | N/A |
| 2023 | $46.16 Million | $1.20 Million | -$14.41 Million | 38.37x | N/A |
| 2024 | $47.07 Million | $2.05 Million | -$19.10 Million | 22.97x | N/A |
Competitor Companies of VF5 by Market Capitalization
Companies near ONDINE BIOMEDICAL INC.CDI in the global market cap rankings as of November 4, 2026. Also see ONDINE BIOMEDICAL INC.CDI total assets for a full breakdown of the balance sheet.
Key companies related to ONDINE BIOMEDICAL INC.CDI by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of ONDINE BIOMEDICAL INC.CDI (2022–2026)
Market capitalization of ONDINE BIOMEDICAL INC.CDI from 2022 to today. Between 2022 and today, ONDINE BIOMEDICAL INC.CDI's market cap moved from $126.34 Million to $ 54.97 Million, with a yearly change of -33.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €54.97 Million | +18.30% |
| 2025 | €46.47 Million | -1.29% |
| 2024 | €47.07 Million | +1.97% |
| 2023 | €46.16 Million | -63.46% |
| 2022 | €126.34 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of ONDINE BIOMEDICAL INC.CDI was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $54.97 Million USD |
| MoneyControl | $54.97 Million USD |
| MarketWatch | $54.97 Million USD |
| marketcap.company | $54.97 Million USD |
| Reuters | $54.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ONDINE BIOMEDICAL INC.CDI
Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, … Read more